Biotechnology and Pharmaceuticals · us
FDA Holds Up ITM’s Radiopharmaceutical Cancer Drug, Manufacturing Deficiencies Delay Potential Novartis Rival’s Market Entry
The FDA did not question ITM-11’s clinical or safety data, but manufacturing and inspection issues at a third-party commercial facility were still enough to block approval, highlighting that competition in radiopharmaceuticals depends not only on efficacy but also on whether supply chains can consistently meet regulatory requirements.
Radiopharmaceuticals are becoming a hotly contested field in cancer treatment, but turning the concept of precision delivery to tumors into a product that can be supplied and inspected remains a challenge. ITM-11, developed by Germany’s ITM Isotope Technologies Munich, failed to secure approval from the U.S. Food and Drug Administration (FDA), delaying its potential entry into the competition for the gastroenteropancreatic neuroendocrine tumor market.
ITM said the company received a complete response letter from the FDA on August 7 regarding the new drug application for ITM-11. The issues raised by the FDA focused on chemistry, manufacturing, and controls (CMC) and included inspection matters concerning a third-party commercial manufacturing facility. This means the application currently does not meet the conditions for approval, but it does not mean the drug has been permanently rejected.
Importantly, according to information disclosed by ITM, the FDA raised no concerns about the clinical or nonclinical data package, identified no new safety issues, and did not request additional clinical or nonclinical studies. This places the focus of the follow-up work on whether deficiencies in the manufacturing process, quality systems, and facility can be corrected, rather than on proving the drug’s efficacy again.
ITM-11, also known as ¹⁷⁷Lu-edotreotide, is a targeted radiopharmaceutical therapy based on the radioactive isotope lutetium-177 and designed for gastroenteropancreatic neuroendocrine tumors. These drugs use molecular carriers that recognize tumor characteristics to bring radiation close to cancer cells. However, isotopes have limited decay periods, so manufacturing, quality release, and distribution must be closely coordinated. If a third-party facility fails to meet regulatory requirements, it may directly affect the entire commercial supply arrangement.
The delay also affects market competition. Novartis has already established a position in radioligand therapy for neuroendocrine tumors, and ITM-11 could offer a new product option if approved. The FDA’s decision temporarily delays this potential competitor’s entry into the U.S. market and again demonstrates that the rapidly expanding radiopharmaceutical industry remains constrained by practical factors including manufacturing capacity, facility compliance, and isotope supply.
ITM is reviewing the FDA’s comments with the relevant external partners and said it intends to resubmit the application. However, the company has not announced a precise timeline for completing corrective actions, holding further discussions with the FDA, or resubmitting the application. The complete response letter has also not been made public, so it is currently impossible to determine the severity of the deficiencies or whether the corrections will take several months or longer.